Ligand id: 2407

Name: fingolimod

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: fingolimod

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 12
Topological polar surface area 66.48
Molecular weight 307.25
XLogP 4.59
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of relapsing-remitting multiple sclerosis (MS) [5]. In May 2018, the FDA approved the use of fingolimod as a treatment for relapsing MS in pediatric patients. This is the first drug to be approved for treating MS in this patient group.
Mechanism Of Action and Pharmacodynamic Effects
Fingolimod is metabolised to the active metabolite fingolimod phosphate by the enzyme sphingosine kinase. Fingolimod phosphate is a modulator of sphingosine receptors (S1P receptors), and its mechanism of action in the treatment of multiple sclerosis is derived from preventing the migration of lymphocytes into the central nervous system where they are implicated in autoimmune-driven demyelination associated with the disease. Clinical side effects (bradycardia, AV block, macular edema) are mostly (but not entirely) linked to S1P3R agonism [1,3,9]. Hence the development of S1P3R-sparing agonists such as compound 43 [PMID: 26751273] [2].
External links